Immunotherapy for head and neck cancer: Recent advances and future directions
JD Cramer, B Burtness, RL Ferris - Oral oncology, 2019 - Elsevier
Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
[HTML][HTML] Immunotherapy for head and neck cancer: Recent advances and future directions
JD Cramer, B Burtness, RL Ferris - Oral oncology, 2019 - ncbi.nlm.nih.gov
Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
[PDF][PDF] Immunotherapy for head and neck cancer: Recent advances and future
JD Cramer, B Burtness, RL Ferris - Oral Oncology, 2019 - bioethics.pitt.edu
Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
Immunotherapy for head and neck cancer: Recent advances and future directions.
JD Cramer, B Burtness, RL Ferris - Oral Oncology, 2019 - europepmc.org
Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
Immunotherapy for head and neck cancer: Recent advances and future directions
JD Cramer, B Burtness, RL Ferris - Oral oncology, 2019 - pubmed.ncbi.nlm.nih.gov
Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
[引用][C] Immunotherapy for head and neck cancer: Recent advances and future directions
JD Cramer, B Burtness, RL Ferris - Oral Oncology, 2019 - cir.nii.ac.jp
[PDF][PDF] Immunotherapy for head and neck cancer: Recent advances and future
JD Cramer, B Burtness, RL Ferris - Oral Oncology, 2019 - bioethics.pitt.edu
Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …